The short version of receptor agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
== Commercial syntheses of amino acids == The commercial production of amino acids usually relies on mutant bacteria that overproduce individual amino acids using glucose as a carbon source. Some amino acids are produced by enzymatic conversions of synthetic intermediates. 2-Aminothiazoline-4-carboxylic acid is an intermediate in the industrial synthesis of L-cysteine for example. Aspartic acid is produced by the addition of ammonia to fumarate using a lyase.
Observe the value of the friction factor for laminar flow at a Reynolds number of 1000. If the value of the friction factor is 0.064, then the Darcy friction factor is plotted in the Moody diagram. Note that the nonzero digits in 0.064 are the numerator in the formula for the laminar Darcy friction factor: fD = 64/Re. If the value of the friction factor is 0.016, then the Fanning friction factor is plotted in the Moody diagram. Note that the nonzero digits in 0.016 are the numerator in the formula for the laminar Fanning friction factor: f = 16/Re. The procedure above is similar for any available Reynolds number that is an integer power of ten. It is not necessary to remember the value 1000 for this procedure—only that an integer power of ten is of interest for this purpose.
=== Development === In November 1990, Warner Bros. Pictures purchased the film rights to "The Rest of Daniel" for $2 million, the most ever paid for a screenplay. Originally intended as a star vehicle for Gibson, he declined the opportunity to direct the feature. The film formed part of a multi-million-dollar three-year distribution deal he signed with Warner Bros., which also guaranteed him a minimum of three months off a year to spend with his family.
In a clinical trial, the group that does not receive the new treatment being studied. This group is compared to the group that receives the new treatment, to see if the new treatment works. (NCI) The standard by which experimental observations are evaluated. In many clinical trials, one group of patients will be given an experimental drug or treatment, while the control group is given either a standard treatment for the illness or a placebo (NLM) Controlled clinical trial
=== December 2004 === Reports of mock executions by the US Marines in Iraq have surfaced in December 2004, as the ACLU published internal documents of the Naval Criminal Investigative Service (NCIS) obtained through the Freedom of Information Act. The documents were written seven weeks after the publication of the photographs which triggered the Abu Ghraib prisoner abuse scandal. Several torture cases were also reported, notably torture by electricity, beatings, and sprayings of prisoners with fire extinguishers. On 21 December, the ACLU released further documents documenting tortures. Notably, in a case of shooting of suspects without warning, Army commanders are reported to have interfered with the investigation. Procedures of autopsy of detainees who died in unclear circumstances have been canceled by battalion and group commands. Other cases include
Sources: en.wikipedia.org
=== Television === Australian actress Zoe Caldwell's performance in the 1982 Broadway adaptation of the Jeffers' script was recorded for broadcast on the PBS series Kennedy Center Tonight. Lars von Trier made a version for television in 1988, based on the script adaptation by Carl Theodor Dreyer. Theo van Gogh directed a miniseries version that aired 2005, the year following his murder. OedipusEnders, a documentary broadcast on BBC Radio 4 on 13 April 2010, discussed similarities between soap opera and Greek theatre. One interviewee revealed that the writers for the ITV police drama series The Bill had consciously and directly drawn on Medea in writing an episode for the series. Playwright Mike Bartlett was inspired to create a modern-day suburban Medea after adapting the Euripides play for a theatre production in 2012. Bartlett's 2015–2017 BBC1 miniseries Doctor Foster follows the structure of the Greek tragedy. A Korean remake of the series, The World of the Married, became the highest-rated cable drama in Korean history, with its final episode reaching a nationwide rating of 28.371%.
== Applications and examples == Exponential decay occurs in a wide variety of situations. Most of these fall into the domain of the natural sciences. Many decay processes that are often treated as exponential, are really only exponential so long as the sample is large and the law of large numbers holds. For small samples, a more general analysis is necessary, accounting for a Poisson process.
Geosphere methane is intriguing for the large input of microbial methanogenesis. This process exhibits a strong KIE, resulting in greater D-depletion in methane relative to other hydrocarbons. δD ranges from −275‰ to −100‰ in thermogenic methane, and from −400‰ to −150‰ in microbial methane. Also, methane formed by marine methanogens is generally enriched in D relative to methane from freshwater methanogens. δD of methane has been plotted together with other geochemical tools (like δ13C, gas wetness) to categorize and identify natural gas. A δD-δ13C diagram (sometimes called CD diagram, Whiticar diagram, or Schoell diagram) is widely used to place methane in one of the three distinct groups: thermogenic methane that is higher in both δ13C and δD; marine microbial methane that is more depleted in 13C and freshwater microbial methane that is more depleted in D. Hydrogenotrophic methanogenesis produces less D-depleted methane relative to acetoclastic methanogenesis. The location where the organism lives and substrate concentration also affect isotopic composition: rumen methanogenesis, which occurs in a more closed system and with higher partial pressures of hydrogen, exhibits a greater fractionation (−300 to −400‰) than wetland methanogenesis (−250 to −170‰).
A low-sulfur diet is a diet with reduced sulfur content. Important dietary sources of sulfur and sulfur containing compounds may be classified as essential mineral (e.g. elemental sulfur), essential amino acid (methionine) and semi-essential amino acid (e.g. cysteine). Sulfur is an essential dietary mineral primarily because amino acids contain it. Sulfur is thus considered fundamentally important to human health, and conditions such as nitrogen imbalance and protein-energy malnutrition may result from deficiency. Methionine cannot be synthesized by humans, and cysteine synthesis requires a steady supply of sulfur.
=== June === On June 1, Davido and Organized Noize were inducted into the Black Music & Entertainment Walk of Fame. On June 2, Peabo Bryson died at the age of 75. On June 3, James Blood Ulmer died at the age of 86. On June 5, Talay Riley was killed at the age of 35. On June 13, the intersection of Grumman Avenue and Elizabeth Avenue in Newark, New Jersey was named Faith Evans Way. On June 16, Flo was awarded the ASCAP Vanguard Award. On June 22, Clive Davis died at the age of 94. On June 25, Leon Thomas was awarded the ASCAP Vanguard Award. On June 28, the BET Awards 2026 were held. Kehlani won Video of the Year for "Folded" and Best Female R&B/Pop Artist. Mariah the Scientist won the Viewer's Choice Award for "Burning Blue". Leon Thomas won Best Male R&B/Pop Artist. Olivia Dean won Best New Artist. Teyana Taylor won Video Director of the Year and received the Icon of the Year Award. Lauryn Hill received the Living Legend Icon Award.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.